Analyst Ratings For Interpace Diagnostics Group (NASDAQ:IDXG)
Today, Laidlaw initiated coverage on Interpace Diagnostics Group (NASDAQ:IDXG) with a Buy with a price target of $4.50.
Some recent analyst ratings include
- 2/22/2018-Laidlaw initiated coverage with a Buy rating.
- 2/14/2018-Maxim Group Reiterated Rating of Buy .
Recent Insider Trading Activity For Interpace Diagnostics Group (NASDAQ:IDXG)
Interpace Diagnostics Group (NASDAQ:IDXG) has insider ownership of 0.70% and institutional ownership of 6.75%.
- On 11/25/2014 Graham G Miao, CFO, bought 22,000 with an average share price of $1.65 per share and the total transaction amounting to $36,300.00.
- On 11/10/2014 Nancy Lurker, CEO, bought 49,000 with an average share price of $1.75 per share and the total transaction amounting to $85,750.00.
- On 11/7/2014 Gerald R Melillo Jr, Insider, bought 5,000 with an average share price of $1.58 per share and the total transaction amounting to $7,900.00.
- On 11/7/2014 Jeffrey Edward Smith, VP, bought 200,000 with an average share price of $1.75 per share and the total transaction amounting to $350,000.00.
- On 11/6/2014 Nancy Lurker, CEO, bought 57,000 with an average share price of $1.74 per share and the total transaction amounting to $99,180.00.
- On 11/5/2014 Gerald P Belle, Director, bought 57,300 with an average share price of $1.71 per share and the total transaction amounting to $97,983.00.
- On 11/18/2013 Gerald Belle, Director, bought 20,400 with an average share price of $5.21 per share and the total transaction amounting to $106,284.00.
Recent Trading Activity for Interpace Diagnostics Group (NASDAQ:IDXG)
Shares of Interpace Diagnostics Group closed the previous trading session at 1.00 up +0.07 7.23% with 1.0199999809265137 shares trading hands.